Skip to main content

CDK4/6 Inhibitors

Incidence of Febrile Neutropenia in Patients With Grade 3 or 4 Neutropenia Who Are Receiving Palbociclib
Katelin Ivey, PharmD, BCPS; Tristan Maiers, PharmD, BCOP; Justine Maley, PharmD
Read More
Online First
Evaluation of Pharmacist-Driven Approach to Monitoring for Neutropenia Related to CDK4/6 Inhibitors in Women With Advanced Breast Cancer
Jianne De Raya, PharmD, and Jessie Modlin, PharmD, BCOP
Read More
Palbociclib-Induced Hepatotoxicity in a Patient with Metastatic Breast Cancer: A Case Report
Jennifer A. Hutchinson, PharmD, BCOP; Jenna Green, BS, PharmD; Christopher Jacques, PharmD; Ju Hee Kim, PharmD; Dana Haggett, MS, RN, FNP-BC; Olivia Straw, MSN, ACNP-BC, AOCNP; Jennifer Shin, MD, MPH
Read More
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
Abstract #CR04
Read More
Resistance Mechanisms to CDK4/6 Blockade in Advanced HR-Positive, HER2-Negative Breast Cancer and Emerging Therapeutic Opportunities
Read More
CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status: A Real-World Evidence Study
Read More
Overall Survival in Patients with HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer Treated with a CDK4/6 Inhibitor plus Fulvestrant: An FDA Pooled Analysis
Read More
Cosela First CDK4/6 Inhibitor FDA Approved to Reduce Chemotherapy-Induced Myelosuppression
Read More
Concurrent Use of Medications with Potential Drug–Drug Interactions: Real-World Analysis of Patients Treated with CDK4/6 Inhibitors
Read More
Examining Different Sequence Effects of CDK4/6 Inhibitor Combinations on Actual Real-World Outcomes of Treatment in Patients with Hormone Receptor–Positive and HER2-Negative Metastatic Breast Cancer
Read More
Page 1 of 3
Results 1 - 10 of 23